Charles River Laboratories International, Inc. (NYSE:CRL) COO Acquires $249,249.82 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) COO Birgit Girshick purchased 1,514 shares of Charles River Laboratories International stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the acquisition, the chief operating officer now owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Charles River Laboratories International Price Performance

NYSE CRL traded up $0.86 on Friday, reaching $163.11. The company’s stock had a trading volume of 1,215,947 shares, compared to its average volume of 1,060,465. Charles River Laboratories International, Inc. has a twelve month low of $150.79 and a twelve month high of $275.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market cap of $8.34 billion, a PE ratio of 1,087.39, a PEG ratio of 6.77 and a beta of 1.37. The firm’s 50 day moving average is $173.39 and its two-hundred day moving average is $188.81.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.16. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business’s revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.46 EPS. As a group, sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on CRL. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. The Goldman Sachs Group reduced their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating for the company in a report on Thursday, January 23rd. Robert W. Baird reduced their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a report on Thursday. Finally, UBS Group reaffirmed a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $195.71.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently bought and sold shares of CRL. Versant Capital Management Inc raised its holdings in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after buying an additional 150 shares during the period. Pinnacle Bancorp Inc. increased its holdings in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 65 shares during the period. Assetmark Inc. grew its stake in shares of Charles River Laboratories International by 1,153.3% in the 3rd quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock valued at $37,000 after buying an additional 173 shares in the last quarter. Optiver Holding B.V. bought a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $37,000. Finally, GeoWealth Management LLC boosted its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company’s stock worth $46,000 after purchasing an additional 190 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).